<DOC>
	<DOCNO>NCT01341184</DOCNO>
	<brief_summary>Evaluation effect rifampin rifabutin single dose PK TMC207 healthy volunteer</brief_summary>
	<brief_title>TMC207 +/- Rifabutin/Rifampin</brief_title>
	<detailed_description>32 ( 16 per treatment group ) healthy male female subject , 18 - 45 year old enrolled.Subjects receive two single oral dos 400mg TMC207 , first Study Day 1 follow 28-day wash-out , second Study Day 29 . On Study Day 28 , abnormal safety lab review study physician determine meet exclusion criterion administration second dose TMC207 . Rifabutin 300mg ( Group 1 ) rifampin 600mg ( Group 2 ) administer daily Period 2 Study Day 20 Study Day 41 . The primary endpoint study ( pharmacokinetics , safety tolerability TMC207 ( M2 metabolite ) determine final study visit , Day 57 ( 28 day last TMC207 dose Period 2 ) .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<mesh_term>Bedaquiline</mesh_term>
	<mesh_term>Diarylquinolines</mesh_term>
	<criteria>Aged 18 45 year , extremes include . Non tobacco/nicotine use ( least 3 month prior screen ) . Body Mass Index ( BMI , weight kg divide square height meter ) 18.0 &lt; 35.0 kg/m^2 Informed Consent Form ( ICF ) sign voluntarily first trialrelated activity . Able comply protocol requirement . Healthy basis medical evaluation history reveals absence clinically relevant abnormality include physical examination , medical history , electrocardiogram ( ECG ) , vital sign , ophthalmologic exam , result blood biochemistry , hematology test , urinalysis carry screening ( See Section 7.2 ) . Subjects enrol study undergone vasectomy/complete hysterectomy , tubal ligation , sterilize procedure , subject postmenopausal woman two year , sexually active subject agree use two follow form adequate contraception study 12 week final dose : abstinence , condom without spermicide gel , diaphragm spermicide gel , hormonal nonhormonal intrauterine device , oral contraceptive pill , depot progesterone injection . If subject usually sexually active becomes active , subject partner must use two listed contraceptive method . Medical History History evidence current use alcohol , barbiturate , amphetamine , recreational , narcotic drug use , investigator 's opinion would compromise subject 's safety and/or compliance trial procedure . Any clinically significant ( deem Principal Investigator ) history acute illness ( resolve within 4 week screen ) , asthma , presence cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal ( include eat disorder ) , endocrine , metabolic , immunologic , dermatologic , neurologic , psychological , psychiatric disease . Currently significant diarrhea , gastric stasis , constipation investigator 's opinion could influence drug absorption bioavailability . Any history significant skin disease , limited , rash eruption , drug allergy , food allergy , dermatitis , eczema , psoriasis , urticaria . Subjects history skin disease may enrol study consultation Sponsor Medical Monitor . Previously demonstrate clinically significant allergy hypersensitivity excipients investigational medication administer trial ( i.e. , rifabutin , rifampin , TMC207 ) . Subjects QTcB [ Bazett correction ] interval &gt; 450ms screen Subjects clinically significant Electrocardiogram ( ECG ) abnormality screening , arrhythmia , ischemia , evidence heart failure family history Long QT Syndrome . History evidence ophthalmologic disease except routine correct hyperopia , myopia , presbyopia . Recent history ( within past 30 day ) vertigo/nausea . Specific Treatments Current use azole antifungal agent Use concomitant medication , include overthecounter product dietary supplement , without approval study staff . Subjects treat base symptom presentation , exception medication affect p450 3a metabolic pathway ( refer MOP list acceptable medication ) . During outpatient time period , subject require discus study staff receive approval selfadministering medication . After gain approval , subject also ask record medication take outpatient time period provide log . Participation investigational drug trial within 60 day prior first intake trial medication duration study . Donation blood significant loss blood within 56 day plasma donation within 7 day precede first intake trial medication . Having receive TMC207 previous trial . Based Laboratory Abnormalities Positive HIV1 HIV2 test Enzymelinked immunosorbent assay ( ELISA ) screening . Hepatitis A , B , C infection ( confirm hepatitis A antibody IgM , hepatitis B surface antigen , hepatitis C virus antibody , respectively ) screening . A positive urine drug test screening . Urine test check current use amphetamine , benzodiazepine , cocaine , cannabinoids , opioids ; along serum alcohol level . Subjects follow laboratory abnormality screen define National Institute Health ( NIH ) , National Institute Allergy Infectious Diseases ( NIAID ) , Division Microbiology Infectious Diseases ( DMID ) Adult Toxicity Table ( Appendix C ) accordance normal range clinical laboratory : 1 . Serum creatinine grade 1 great [ &gt; 1.0 x Upper limit lab normal range ( ULN ) ] , 2 . Pancreatic lipase grade 1 great ( &gt; 1.0 x ULN ) , 3 . Hemoglobin grade 1 great ( &lt; /= 10.5 g/dL ) , 4 . Platelet count grade 1 great ( &lt; /= 99000/mm^3 ) , 5 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) grade 1 great ( &gt; 1.0 x ULN ) , 6 . Total bilirubin grade 1 great ( &gt; 1.0 x ULN ) , 7 . Creatine kinase grade 1 great ( &gt; 1.0 x ULN ) , 8 . Troponin grade 1 great ( 1.0 x UNL ) , 9 . Any toxicity grade 2 , include : proteinuria ( spot urine ) &gt; 1+ gross hematuria . For second dose TMC207 , toxicity grade 3 , include : proteinuria ( spot urine ) &gt; 1+ gross hematuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>tuberculosis , rifabutin , rifampin , TMC207</keyword>
</DOC>